Target Engagement of Terazosin in Healthy Adults

• Status: Recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the target engagement of Terazosin (TZ) in a single cohort of 6 healthy adult participants. During the study participants will undergo PET/CT scans, 7-Tesla MRI scans, blood draws, and an optional lumbar puncture (LP.)

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Iowa
• Collaborator: Michael J. Fox Foundation for Parkinson's Research
• Treatments: Terazosin

Criteria

Inclusion Criteria:

• Healthy Men or women aged 60-90

Exclusion Criteria:

• History of stroke

• Ineligibility for MRI (e.g. soft tissue metallic implants, clips, cardiac pacemaker, cardiac defibrillator, internal pacing wires, metallic fragments, shrapnel, etc.)

• Current use of more than one of the following classes of medications: beta blockers, ace inhibitors, angiotensin receptor blockers, calcium channel blockers, or diuretics

• Use of any alpha blockers (terazosin, doxazosin, alfuzosin, prazosin, or tamsulosin) in the past year.

• Current use of the over-the-counter supplement yohimbe

• Orthostatic hypotension defined as symptomatic decrease in BP > 20mmHg systolic or > 10mmHg diastolic and HR increase < 20bpm on supine to sitting or standing.

• Alcohol and drug abuse

• Clinically significant traumatic brain injury

• History of Type I diabetes

• Uncontrolled Type II diabetes

• Other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study or increase fall risk

• Use of investigational drugs within 30 days before screening

• History of hemodynamic instability

• For females: pregnancy or breastfeeding